SPP-DM1 (CAT#: ADC-S-050)

Linker-Toxin SET, this set is made by DM1 conjugated to SPP linker. DM1 belongs to Maytansinoids which are a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, interfering the formation of microtubule.

Product Information

CAS NO
452072-20-7

Description
Linker-Toxin SET, this set is made by DM1 conjugated to SPP linker. DM1 belongs to Maytansinoids which are a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, interfering the formation of microtubule.

Molecular Weight
967.54

Purity
95%

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-S-050. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

PP-DM1 has proven to be an excellent tool in my ADC research. The linker-toxin combination provides a highly efficient means of delivering cytotoxic payloads to target cells with minimal off-target effects.

Excellent

Using SPP-DM1 has significantly improved the quality of our experiments. The linker and toxin conjugation is stable, leading to consistent results when targeting cancer cells. Highly recommended for those in the field of targeted therapies.

Excellent

I've seen great success utilizing SPP-DM1 in ADC development. It delivers its cytotoxic payload effectively, and the conjugation to the SPP linker enhances its specificity to target cells in my research.

Excellent

SPP-DM1 has been a game-changer in our lab's targeted cancer therapy studies. It allows for precise targeting of cancer cells, reducing the need for higher concentrations of toxins and minimizing side effects.

Excellent

I used SPP-DM1 in a series of cancer cell assays, and the performance was outstanding. The compound worked efficiently, showing potent cytotoxic effects at low concentrations. It's a vital component in my ongoing research.

Q: 1: What is SPP-DM1, and how does it function in ADC development?
A: SPP-DM1 is a tubulin inhibitor conjugated to antibodies in ADCs. It works by disrupting microtubule formation in cancer cells, leading to cell cycle arrest and apoptosis, providing targeted cytotoxicity.
Q: 2: Can SPP-DM1 be used with various antibodies in ADCs?
A: Yes, SPP-DM1 can be conjugated to antibodies targeting different antigens. Its compatibility with a wide range of antibodies allows for versatile ADC designs against various cancers.
Q: 3: How does SPP-DM1 enhance the cytotoxicity of ADCs?
A: SPP-DM1 releases DM1, a potent cytotoxic agent, upon internalization into tumor cells. DM1 binds to tubulin, disrupting microtubule dynamics, leading to cancer cell death and improved efficacy of ADCs.
Q: 4: What preclinical models are used to evaluate SPP-DM1-based ADCs?
A: SPP-DM1-based ADCs are typically tested in animal models of breast, ovarian, and lung cancers. These models help assess the targeting efficiency, pharmacokinetics, and therapeutic potential of the ADCs.
Q: 5: How does SPP-DM1 affect the immune system in ADC therapy?
A: SPP-DM1 primarily targets tumor cells and has minimal direct effects on the immune system. However, by reducing tumor burden, it may indirectly enhance immune responses against residual cancer cells in immuno-oncology applications.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.